NEW DELHI : As COVID-19 vaccine trials move ahead at a break-neck speed, an approved vaccine is likely to hit the Indian market by the first quarter of 2021, Bernstein said in a report.Globally, there are 4 candidates that are close to approval by the end of 2020 or early 2021.Through partnerships, India has access to two of those – AZ/Oxford's viral vector vaccine and Novavax's protein subunit vaccine."Phase I/II data looks promising for both in terms of safety and the vaccine's ability to elicit an immune response," it said. "We are optimistic that there will be an approved vaccine in the market by 1Q calendar year 2021 in India."While the vaccine could be available at USD 3-6 ( ₹225 to ₹550) per dose, herd immunity might be two years.